Señales en vivo de TPST | Maximiza tus Ganancias con Getagraph.com

VENDER 106399 min ago

@ $4.10

Emitido: 14 feb 2024 @ 09:30

Retorno: -13.66%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: -0.93 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	402 127
Volumen promedio	979 955
Capitalización de mercado	78.65M
EPS	$0 ( 2024-03-27 )
Próxima fecha de ganancias	( $-0.440 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0.0120 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Brady Stephen R	Buy	250 000	Employee Stock Option (right to buy)
2024-01-03	Whiting Samuel	Buy	100 000	Employee Stock Option (right to buy)
2024-01-03	Trojanowski Justin	Buy	26 500	Employee Stock Option (right to buy)
2024-01-03	Maestas Nicholas	Buy	40 000	Employee Stock Option (right to buy)
2023-10-11	Brady Stephen R	Buy	725 000	Employee Stock Option (right to buy)

INSIDER POWER
99.69
Last 85 transactions
Buy: 12 322 880 \| Sell: 50 340

Volumen Correlación

Largo: 0.01 (neutral)

Corto: -0.68 (moderate negative)

Signal:(42.86) Neutral

Tempest Therapeutics, Correlación

10 Correlaciones Más Positivas
SIFY	0.842
SVOK	0.816
FORE	0.814

10 Correlaciones Más Negativas
RAVN	-0.856

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tempest Therapeutics, Correlación - Moneda/Commodity

0.58
( weak )

0.66
( moderate )

0.00
( neutral )

0.66
( moderate )

0.00
( neutral )

-0.05
( neutral )

Tempest Therapeutics, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.81M (0.00 %)
EPS:	$-3.18

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-4.27

Financial Reports:

No articles found.

Tempest Therapeutics,

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.